Biotechnology
Biopharmaceutical
Pharmaceutical

AMAG Pharmaceuticals

$12.46
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

$0.00 (0.00%) Today
$0.00 (0.00%) Today

Why Robinhood?

You can buy or sell AMAG and other stocks, options, ETFs, and crypto commission-free!

About

AMAG Pharmaceuticals, Inc. Common Stock, also called AMAG Pharmaceuticals, is a biopharmaceutical company, which focuses on the research, development, and commercialization of a therapeutic iron compound to treat iron deficiency anemia. Read More The firm focuses on the development and commercialization of Feraheme injection for intravenous use to treat iron deficiency anemia. It manufactures, develops, and commercializes products derived from its proprietary technology for use in treating human diseases. Its products include Intrarosa, Makena, CBR, Feraheme, and MuGard. The company was founded on November 9, 1981 and is headquartered in Waltham, MA.

Employees
467
Headquarters
Waltham, Massachusetts
Founded
1981
Market Cap
431.20M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
720.55K
High Today
$12.53
Low Today
$12.00
Open Price
$12.40
Volume
193.20K
52 Week High
$26.10
52 Week Low
$10.70

Collections

Biotechnology
Biopharmaceutical
Pharmaceutical
Manufacturing
Health
Technology
Therapy
US

News

MarketWatch5h

AMAG Pharmaceuticals Inc.

Shares of AMAG Pharmaceuticals Inc. fell 6% after the company announced that its Phase 3 trial of Makena, a progestin therapy to reduce the risk of preterm birth, did not meet its primary endpoints. The trial, which enrolled 1700 patients, did not show a statistically significant difference between the treatment and placebo arms in preterm deliveries at less than 35 weeks. The trial also did not show a difference in neonatal morbidity and mortality, the company said. Makena is currently approved as a therap...

19
Yahoo Finance6h

March of Dimes and AMAG Pharmaceuticals, Inc., Announce First Joint Supportive Pregnancy Care Program

First Site Launches in Springfield, Mass. Offering an Innovative Model of Group Prenatal Care ARLINGTON, Va. and WALTHAM, Mass., March 20, 2019 (GLOBE NEWSWIRE) -- March of Dimes and AMAG Pharmaceuticals, Inc. (AMAG) today announced Baystate Medical Center’s Wesson Women’s Clinic in Springfield, Mass. as the first Supportive Pregnancy Care (SPC) site, supported by AMAG to help improve mom and baby health during pregnancy, labor and delivery, and infancy. The March of Dimes SPC program offers prenatal ca...

14
Simply Wall StMar 14

Volatility 101: Should AMAG Pharmaceuticals (NASDAQ:AMAG) Shares Have Dropped 41%?

Ideally, your overall portfolio should beat the market average. But the main game is to find enough winners to more than offset the losers So we wouldn’t blame long term AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) shareholders for doubting their decision to hold, with the stock down 41% over a half decade. And it’s not just long term holders hurting, because the stock is down 35% in the last year. Shareholders have had an even rougher run lately, with the share price down 24% in the last 90 days. This could be...

105

Earnings

-$1.59
-$0.61
$0.36
$1.34
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Estimated
Actual
Expected May 2, Pre-Market
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.